Roivant Shares Rise On Positive Data for Autoimmune Disease Drug

Dow Jones

Sep 17

By Nicholas G. Miller

Shares of Roivant rose in premarket trading after the company released positive data from a phase three study of brepocitinib, a drug to treat Dermatomyositis, an autoimmune disease.

The stock was up 3.8% to $14.72 after closing Tuesday up 20% so far this year.

The company said brepocitinib demonstrated a statistically-significant improvement when compared to a placebo on its primary end point and all nine key secondary endpoints.

More than two-thirds of patients experienced at least a moderate response from the drug with almost half experiencing a major response.

The company plans to file a new drug application for the drug in the first half of next year.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

September 17, 2025 07:35 ET (11:35 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2568493326"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568493326\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568493326?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-17 19:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568493326","market":"us","top_or_hot":-1,"title":"Roivant Shares Rise On Positive Data for Autoimmune Disease Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Roivant rose in premarket trading after the company released positive data from a phase three study of brepocitinib, a drug to treat Dermatomyositis, an autoimmune disease. \n</p>\n<p>\n  The stock was up 3.8% to $14.72 after closing Tuesday up 20% so far this year. \n</p>\n<p>\n  The company said brepocitinib demonstrated a statistically-significant improvement when compared to a placebo on its primary end point and all nine key secondary endpoints. \n</p>\n<p>\n  More than two-thirds of patients experienced at least a moderate response from the drug with almost half experiencing a major response. \n</p>\n<p>\n  The company plans to file a new drug application for the drug in the first half of next year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 17, 2025 07:35 ET (11:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roivant Shares Rise On Positive Data for Autoimmune Disease Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoivant Shares Rise On Positive Data for Autoimmune Disease Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-17 19:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Roivant rose in premarket trading after the company released positive data from a phase three study of brepocitinib, a drug to treat Dermatomyositis, an autoimmune disease. \n</p>\n<p>\n  The stock was up 3.8% to $14.72 after closing Tuesday up 20% so far this year. \n</p>\n<p>\n  The company said brepocitinib demonstrated a statistically-significant improvement when compared to a placebo on its primary end point and all nine key secondary endpoints. \n</p>\n<p>\n  More than two-thirds of patients experienced at least a moderate response from the drug with almost half experiencing a major response. \n</p>\n<p>\n  The company plans to file a new drug application for the drug in the first half of next year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 17, 2025 07:35 ET (11:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2568493326","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568493326","pubTimestamp":1758108900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Roivant rose in premarket trading after the company released positive data from a phase three study of brepocitinib, a drug to treat Dermatomyositis, an autoimmune disease.The stock was up 3.8% to $14.72 after closing Tuesday up 20% so far this year.The company said brepocitinib demonstrated a statistically-significant improvement when compared to a placebo on its primary end point and all nine key secondary endpoints.More than two-thirds of patients experienced at least a moderate response from the drug with almost half experiencing a major response.The company plans to file a new drug application for the drug in the first half of next year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd.","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Roivant股价因自身免疫性疾病药物的积极数据而上涨","themeId":"bf1f9917e89d16c929d49ce909869251","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":0.9},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Shares of Roivant rose in premarket trading after the company released positive data from a phase three study of brepocitinib, a drug to treat Dermatomyositis, an autoimmune disease. \n\n\n  The stock was up 3.8% to $14.72 after closing Tuesday up 20% so far this year. \n\n\n  The company said brepocitinib demonstrated a statistically-significant improvement when compared to a placebo on its primary end point and all nine key secondary endpoints. \n\n\n  More than two-thirds of patients experienced at least a moderate response from the drug with almost half experiencing a major response. \n\n\n  The company plans to file a new drug application for the drug in the first half of next year. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 17, 2025 07:35 ET (11:35 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}